Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 11/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12553326 | 0.87 | GSK3B (0.68) | GSK3BALDH1A1MAPTVNN1GRM5 | |
| SCHEMBL8105775 | 0.81 | GSK3B (0.74) | GSK3BALDH1A1MAPTVNN1GRM5 | |
| SCHEMBL3765830 | 0.81 | MAPT (0.52) | GSK3BALDH1A1MAPTHSP90AA1HPGD | |
| SCHEMBL3765733 | 0.81 | MAPT (0.56) | ALDH1A1MAPTHSP90AA1HPGDHTT | |
| SCHEMBL3973753 | 0.81 | ALDH1A1 (0.52) | GSK3BALDH1A1MAPTHSP90AA1HPGD | |
| SCHEMBL3760982 | 0.81 | MAPT (0.52) | GSK3BALDH1A1MAPTHSP90AA1HPGD | |
| SCHEMBL12553443 | 0.80 | HSD17B10 (0.61) | GSK3BALDH1A1MAPTHPGDVNN1 | |
| SCHEMBL1712250 | 0.80 | GSK3B (0.72) | GSK3BALDH1A1MAPTVNN1GRM5 | |
| SCHEMBL14415181 | 0.79 | MAPT (0.51) | GSK3BALDH1A1MAPTHSP90AA1HPGD | |
| SCHEMBL955563 | 0.79 | ALDH1A1 (0.56) | GSK3BALDH1A1MAPTHSP90AA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| CN-101103007-A | Amide compound | TAKEDA PHARMACEUTICAL (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | GSK3B 4463/4885ALDH1A1 353/4885MAPT 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.